Pre-clinical Bruker Albira Si PET/SPECT/CT imaging system

项目摘要/摘要 斯坦福大学医学院放射学系是一所著名的机构，以 开发下一代成像技术、分子成像、体外诊断、图像引导 治疗学，以及精确健康的信息学。我们在斯坦福大学的分子成像计划(MIPS)，一个高度 公认的跨学科研究部门成立于2003年，汇集了科学家和医生，他们 在开发和使用最先进的成像技术和开发分子方面有共同的兴趣 用于研究完整生物系统的成像分析。现在有一种迫切的、未得到满足的方案需求 多模式小动物成像系统，提供最先进的成像在Bruker AlBira Si PET/SPECT/CT。它将是斯坦福大学的一项使能技术，为多领域的研究创造新的机会 示踪成像，大大扩展了我们的放射性核素储备，超越了正电子发射器，并加速了 新放射性药物开发和临床翻译在我们的诊断学计划。它将允许 我们曾经最先进但现在已经寿终正寝的主力Inveon PET/CT的日落，它经历了 由于故障而增加停机时间。它将被放置在我们综合的小动物成像设施中作为 斯坦福大学共享资源，并得到一支博士级资深科学家团队的支持。一种综合三模成像技术 系统将立即为我们完善和不断增长的基于放射性核素的生物标志物的发现做出贡献 诊断学和放射配基治疗课程。我们收集的主要用户和次要用户反映的是初级用户 通过NIH资助的研究项目的高级教员，并包括各自领域的高度成就的专家。 他们对多示踪剂应用特别感兴趣，因此，集成系统结合 特别需要SPECT、PET和CT。核成像模式将支持我们的研究人员，他们 研究图像引导的药物输送、癌症生物学、神经疾病、癌细胞和基因疗法，以及 除了开发新的诊断和治疗放射性药物外，免疫和免疫治疗 和成像策略。SPECT对于需要获得生物标记物以外的生物标记物的研究人员来说是必不可少的 可同时对多个目标进行成像。两种方式，当与解剖CT相结合时， 对于推动新的放射性药物从发现到人类第一临床翻译是必不可少的，并将 成为我们不断扩大的神学活动的核心。这台仪器的加入将与 斯坦福大学的计划活动：新的最先进的回旋加速器和放射化学设施，首次指定 卓越的综合放射药物治疗中心，对放射诊断学和 生物标记物的发现和生物医学物理、成像和基于放射性核素的新的教育机会 心理治疗。AlBira系统将在小动物研究方面创造新的机会，并与斯坦福大学的 以远大视野引领生物医学创新和先进精准医学。

PROJECT SUMMARY/ABSTRACT The Department of Radiology at the Stanford School of Medicine is a preeminent institution renown for developing next generation imaging technology, molecular imaging, in vitro diagnostics, image-guided therapeutics, and informatics for precision health. Our Molecular Imaging Program at Stanford (MIPS), a highly regarded interdisciplinary research division established in 2003, brings together scientists and physicians who share a common interest in developing and using state-of-the-art imaging technology and developing molecular imaging assays for studying intact biological systems. There is now a pressing unmet programmatic need for a multimodal small animal imaging system that offers state-of-the-art imaging available in the Bruker Albira Si PET/SPECT/CT. It will be an enabling technology at Stanford, creating new research opportunities for multi- tracer imaging, significantly broadening our repertoire of radionuclides beyond positron-emitters and accelerating novel radiopharmaceutical development and clinical translation in our theragnostics program. It will allow sunsetting of our once-state-of-the-art, but now end-of-life workhorse Inveon PET/CT, which has experienced increasing downtime due to failures. It will be placed in our comprehensive small animal imaging facility as a Stanford shared resource and supported by a team of PhD-level senior scientists. An integrated trimodal imaging system will immediately contribute to our well-established and growing radionuclide-based biomarker discovery program in diagnostics and radioligand therapy. The Major and Minor users we have assembled reflect junior through senior faculty with NIH-funded research projects and includes highly accomplished experts in their fields. They are particularly interested in multi-tracer applications and, therefore, an integrated system combining SPECT, PET and CT is especially needed. The nuclear imaging modalities would support our researchers who study image-guided drug delivery, cancer biology, neurological diseases, cancer cell and gene therapies, and immunity and immunotherapy, in addition to developing novel diagnostic and theragnostic radiopharmaceuticals and imaging strategies. SPECT is essential for researchers who need access to biomarkers outside of those for PET and for imaging more than one target concurrently. Both modalities, when combined with anatomical CT, are essential to advance novel radiopharmaceuticals from discovery to first-in-human clinical translation, and will be central to our expanding theragnostics activities. The addition of this instrument will converge with programmatic activities at Stanford: new state-of-the-art cyclotron and radiochemistry facility, first designated comprehensive Radiopharmaceutical Therapy Center of Excellence, growing interest in theragnostics and biomarker discovery, and new educational opportunities in biomedical physics, imaging and radionuclide-based therapy. The Albira system will create novel opportunities in small animal research and synergize with Stanford’s long-range vision to lead in biomedical innovation and advanced precision medicine.